Browse Items · NEOMED Bibliography Database

An update on the association of vitamin D deficiency with common infectious diseases.

Vitamin D plays an important role in modulating the immune response to infections. Deficiency of vitamin D is a common condition, affecting both the general population and patients in health care facilities. Over the last decade, an increasing body…

Omadacycline: A novel tetracycline derivative with oral and intravenous formulations.

Omadacycline, an aminomethylcycline, is a novel member of the tetracycline class of antibiotics. It has received approval by the U.S. Food and Drug Administration (FDA) for treatment of community-acquired bacterial pneumonia (CABP) and acute…

Tags: 2019, ABSSSI, antibiotic, Antimicrobial resistance, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Department of Internal Medicine, Deresinski Stan, NEOMED College of Medicine, omadacycline, Pneumonia, Watkins Richard R

Subglottic Secretion Suctioning Reduces Vent-Associated Pneumonia, Antibiotic Use.

Tags: 2014, Academic Medical Centers, Antibiotics, Belgium, Confidence Intervals, Department of Internal Medicine, Endotracheal – Utilization, Human, Infectious Disease Alert, NEOMED College of Medicine, Odds Ratio, Pneumonia, RANDOMIZED controlled trials, Secretions, Suctioning, Ventilator-Associated – Prevention and Control, Watkins Richard R

Respiratory infections unique to Asia

Asia is a highly heterogeneous region with vastly different cultures, social constitutions and populations affected by a wide spectrum of respiratory diseases caused by tropical pathogens. Asian patients with community-acquired pneumonia differ from…

Management of community-acquired pneumonia: a focus on conversion from hospital to the ambulatory setting.

Patients with community-acquired pneumonia (CAP) are treated in hospital or in the ambulatory care setting depending on the severity of illness. Despite numerous guidelines proposed, there is no agreement on specific criteria for hospitalization…

Tags: *Ambulatory Care, *Hospitalization, 2003, American journal of respiratory medicine : drugs, devices, and other interventions, Anti-Bacterial Agents/*administration & dosage, Bacterial/*therapy, Community-Acquired Infections/therapy, Department of Internal Medicine, File Thomas M Jr, Humans, NEOMED College of Medicine, Pneumonia, Tan James S

Ambulatory management of lower respiratory tract infections.

Clinical manifestations and radiographic findings are unreliable guides to the selection of antimicrobial therapy for lower respiratory infections. Laboratory evaluation is necessary to identify the etiologic agent. Multiple oral antibiotics are…

Tags: 1991, American family physician, Anti-Bacterial Agents/*therapeutic use, Bacterial Infections/drug therapy, Department of Internal Medicine, File T M Jr, Humans, Legionnaires' Disease/diagnosis, Mycoplasma/diagnosis, NEOMED College of Medicine, Pneumonia, Pneumonia/*diagnosis/*drug therapy, Tan J S, Thomson R B Jr

Role of 'atypical' pneumonia pathogens in respiratory tract infections.

The 'atypical' pathogens are important causes of pneumonia, causing illness ranging from mild to life-threatening. The most common atypical pathogens are Mycoplasma pneumoniae and Chlamydia pneumoniae; others include Legionella species, Chlamydia…

Tags: 1999, Bacterial/diagnosis/*microbiology, Canadian respiratory journal, Chlamydia Infections, Chlamydophila pneumoniae, Community-Acquired Infections, Humans, Immunoenzyme Techniques, Legionella pneumophila, Mycoplasma/diagnosis/*microbiology, Pneumonia, Polymerase Chain Reaction, Tan J S

Ceftaroline fosamil versus ceftriaxone for the treatment of community-acquired pneumonia: individual patient data meta-analysis of randomized controlled trials.

BACKGROUND: We conducted a meta-analysis of clinical trials of adults hospitalized with pneumonia outcomes research team (PORT) risk class 3-4 community-acquired pneumonia (CAP) receiving ceftaroline fosamil versus ceftriaxone. METHODS: Three Phase…

Managing patients with recurrent acute exacerbations of chronic bronchitis: a common clinical problem

Chronic obstructive pulmonary disease (COPD) affects 15 million people and is the fourth leading cause of death in the United States. It places a considerable burden on the healthcare system, with exacerbations contributing to a significant…

Identifying Barriers to Adult Pneumococcal Vaccination: An NFID Task Force Meeting

Pneumococcal infection is common in adults, and invasive disease is associated with a high mortality rate. Pneumococcal polysaccharide vaccine can prevent invasive pneumococcal disease and is recommended for people aged >= 65 years and for younger…

Tags: 2012, adult vaccination, care, Disease, File T M, General & Internal Medicine, Influenza, Journal Article, Metersky M, Natl Fdn Infect Dis Pneumococcal D, Nichol K L, pneumococcal disease, Pneumococcal Vaccine, Pneumonia, Postgraduate medicine, Rehm S J, Schaffner W, Streptococcus pneumoniae, united-states

Higher Pneumococcal Disease Vaccination Rates Needed to Protect More At-Risk US Adults

Pneumococcal disease, which includes pneumococcal pneumonia, meningitis, and bacteremia, is associated with substantial morbidity, mortality, and health care costs in adults. Advanced age, chronic lung or cardiovascular disease, immunosuppressive…

Treatment of community-acquired pneumonia in immunocompromised adults: A consensus statement regarding initial strategies

Background Community-acquired pneumonia (CAP) guidelines have improved the treatment and outcomes of patients with CAP, primarily by standardization of initial empirical therapy. But current society-published guidelines exclude immunocompromised…

Aspiration pneumonia, necrotizing pneumonia, and lung abscess.

Suppurative complications to aspiration pneumonia occur if the initial aspiration and subsequent pneumonitis go unrecognized or untreated. Anaerobic cavitary disease is typically an indolent process, whereas necrotizing pneumonia is more fulminant…

Tags: 1989, Aspiration/diagnosis/*pathology/physiopathology/therapy, Combined Modality Therapy, Department of Internal Medicine, Emergency medicine clinics of North America, Humans, Lung Abscess/diagnosis/etiology/*therapy, Necrosis, NEOMED College of Medicine, Pennza P T, Pneumonia

The relationship between psychiatric medication and course of hospital stay among intoxicated trauma patients

Introduction The purpose of this study was to determine whether trauma patients requiring psychiatric medication who were admitted with positive alcohol or drug screen require more pain medications or sedation resulting in longer length of stay.…

Epidemiology, microbiology, and treatment considerations for bacterial pneumonia complicating influenza

Post-influenza bacterial pneumonia is a major cause of morbidity and mortality associated with both seasonal and pandemic influenza virus illness. However, despite much interest in influenza and its complications in recent years, good clinical trial…

Pediatric airway management in COVID-19 patients: consensus guidelines from the society for pediatric anesthesia's pediatric difficult intubation collaborative and the Canadian Pediatric Anesthesia Society.

The severe acute respiratory syndrome coronavirus 2 (coronavirus disease 2019 [COVID-19]) pandemic has challenged medical systems and clinicians globally to unforeseen levels. Rapid spread of COVID-19 has forced clinicians to care for patients with a…

Tags: 2020, Adolescent, Airway Management/ methods, Anesthesia and Analgesia, Anesthesia/methods, Anesthesiology/ methods/standards, Asaf S, Ayad I, Bhalla T, Castro P, Chiao F, Child, Consensus, Coronavirus Infections/ therapy, Crockett C, Dalesio N, Denning S, Department of General Surgery, Disma N, Engelhardt T, Evans F, Fiadjoe JE, Galvez I, Gálvez J, Garcia-Marcinkiewicz A, Glover C, Gooden C, Greenberg R, Greenwood E, Guidelines as Topic, Gumaney H, Haydar B, Hervías M, Hsu G, Humans, Hunyady A, Infant, Infection Control, Infectious Disease Transmission, Ingelmo P, Intratracheal/ methods/standards, Intubation, Jagannathan N, Javia L, journalArticle, July 2020 List, Kiss EE, Kovatsis PG, Lardner D, Lau J, Lee JK, Lee LK, Lockman JL, Matava CT, Matuszczak M, McCloskey J, Mireles S, NEOMED College of Medicine, Newborn, Olomu P, Pandemics, Park R, Patient-to-Professional/prevention & control, Pediatrics/ methods/standards, Pérez-Pradilla C, Peyton J, Pneumonia, Polaner D, Preschool, Raman VT, Rehman M, Reynolds P, Sabato S, Stein ML, Szmuk P, Szolnoki J, Taicher B, Tan J, Templeton T, Theroux MC, Thompson N, Viral/ therapy, Von Ungern-Sternberg B, Whyte S, Yaster M, Yu J

Bacterial Pneumonia in Older Adults.

Community-acquired pneumonia is common in the elderly person; its presentation in this population is often confounded by multiple comorbid illnesses, including those that result in confusion. Although severity-of-illness scoring systems might aid…

Assessment of time to clinical response, a proxy for discharge readiness, among hospitalized patients with community-acquired pneumonia who received either ceftaroline fosamil or ceftriaxone in two phase III FOCUS trials.

The primary driver of health care costs for patients with community-acquired pneumonia (CAP) is the hospital length of stay (LOS). Unfortunately, hospital LOS comparisons are difficult to make from phase III CAP trials because of their structured…

Comparison of narrow-versus broad-spectrum antibiotics in elderly patients with acute exacerbations of chronic obstructive pulmonary disease

Background Little evidence is available regarding the choice of empiric antibiotic therapy in elderly patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD). The primary objective of this study is to compare the outcomes…

Pneumococcal epidemiology among us adults hospitalized for community-acquired pneumonia

BACKGROUND: Few studies have measured the burden of adult pneumococcal disease after the introduction of 13-valent pneumococcal conjugate vaccine (PCV13) into the US infant vaccination schedule. Further, most data regarding pneumococcal serotypes are…

Expanded Analysis of 20 Pneumococcal Serotypes Associated With Radiographically Confirmed Community-Acquired Pneumonia in Hospitalized US Adults.

Background: Streptococcus pneumoniae is a causative agent of community-acquired pneumonia (CAP). The 13-valent pneumococcal conjugate vaccine (PCV13) has significantly decreased the burden of PCV13-serotype pneumococcal disease; however, disease due…

Expanded Analysis of 20 Pneumococcal Serotypes Associated With Radiographically Confirmed Community-Acquired Pneumonia in Hospitalized US Adults.

Streptococcus pneumoniae is a causative agent of community-acquired pneumonia (CAP). The 13-valent pneumococcal conjugate vaccine (PCV13) has significantly decreased the burden of PCV13-serotype pneumococcal disease; however, disease from nonvaccine…

Tags: 20-valent pneumococcal conjugate vaccine, 2021, Adult, Pneumonia, serotypes, urinary antigen detection

Spectrum of excess mortality due to carbapenem-resistant Klebsiella pneumoniae infections.

Patients infected or colonized with carbapenem-resistant Klebsiella pneumoniae (CRKp) are often chronically and acutely ill, which results in substantial mortality unrelated to infection. Therefore, estimating excess mortality due to CRKp infections…

Tags: *beta-Lactam Resistance, 2016, 80 and over, Aged, Bacteremia/microbiology/mortality, Bacterial/microbiology/mortality, Bonomo R A, carbapenem-resistant Enterobacteriaceae, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, Cober E, Department of Internal Medicine, Doi Y, Epidemiology, Evans S, Female, Fowler V G Jr, Hauck C, Humans, Kalayjian R C, Kaye K S, Klebsiella Infections/*microbiology/*mortality, Klebsiella pneumoniae, Klebsiella pneumoniae/*drug effects/isolation & purification, Longitudinal Studies, Male, Middle Aged, Mortality, NEOMED College of Medicine, Perez F, Pneumonia, Prospective Studies, Richter S S, Salata R A, Scalera N M, Survival Analysis, Urinary Tract Infections/microbiology/mortality, van Duin D, Watkins R R

LVC Timing in Infant Pig Swallowing and the Effect of Safe Swallowing.

Recurrent laryngeal nerve (RLN) injury in neonates, a complication of head and neck surgeries, leads to increased aspiration risk and swallowing dysfunction. The severity of resulting sequelae range from morbidity, such as aspiration pneumonia, to…

Pre-pharyngeal Swallow Effects of Recurrent Laryngeal Nerve Lesion on Bolus Shape and Airway Protection in an Infant Pig Model.

Recurrent laryngeal nerve (RLN) damage in infants leads to increased dysphagia and aspiration pneumonia. Recent work has shown that intraoral transport and swallow kinematics change following RLN lesion, suggesting potential changes in bolus…

Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial.

BACKGROUND: Lefamulin, a pleuromutilin antibiotic, is active against pathogens commonly causing community-acquired bacterial pneumonia (CABP). The Lefamulin Evaluation Against Pneumonia (LEAP 1) study was a global noninferiority trial to evaluate…

Tags: 2019, Administration Intravenous, Adult, Aged, Anti-Bacterial Agents/administration & dosage/adverse effects/therapeutic use, antibiotic, Clinical Infectious Diseases, Das A, Diterpenes/administration & dosage/adverse effects/therapeutic use, Double-Blind Method, Female, File TM, Gasink LB, Gelone SP, Goldberg L, Hospital List, Humans, journalArticle, lefamulin, Linezolid/adverse effects/therapeutic use, Male, Microbial Sensitivity Tests, Middle Aged, Moxifloxacin, Moxifloxacin/administration & dosage/adverse effects/therapeutic use, Paukner S, pleuromutilin, Pneumonia, Pneumonia Bacterial/drug therapy/metabolism, Polycyclic Compounds/administration & dosage/adverse effects/therapeutic use, Randomized Controlled Trials as Topic, Saviski J, Seltzer E, Sweeney C, Talbot GH, Thioglycolates/administration & dosage/adverse effects/therapeutic use, Wicha WW

Summary of ceftaroline fosamil clinical trial studies and clinical safety.

In October 2010, the new cephalosporin, ceftaroline fosamil, was approved by the US Food and Drug Administration for therapy of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSIs). The active…

Tags: 2012, Anti-Bacterial Agents/adverse effects/*therapeutic use, Bacterial/drug therapy, Cephalosporins/adverse effects/*therapeutic use, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Clinical Trials as Topic, Department of Internal Medicine, File Thomas M Jr, Humans, NEOMED College of Medicine, Pneumonia, Staphylococcal Skin Infections/drug therapy, Stein Gary E, Wilcox Mark H

International guidelines for the treatment of community-acquired pneumonia in adults: the role of macrolides.

The significance of community-acquired pneumonia (CAP) has led to the publication of guidelines from numerous international organisations. Because the macrolide class of antimicrobials is active against most of the key pathogens associated with CAP,…

Strategies for improving antimicrobial use and the role of antimicrobial stewardship programs.

What can we learn from the time course of untreated and partially treated community-onset Streptococcus pneumoniae pneumonia? A clinical perspective on superiority and noninferiority trial designs for mild community-acquired pneumonia.

There are no well-designed placebo-controlled clinical trials in the recent era that precisely define the magnitude of the drug effect of antimicrobial therapy for mild community-acquired pneumonia (CAP). However, there is evidence that ineffective…

Tags: *Research Design, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Community-Acquired Infections/*drug therapy/microbiology, Department of Internal Medicine, Disease Progression, File Thomas M Jr, Humans, NEOMED College of Medicine, Pneumococcal/*drug therapy/microbiology, Pneumonia, Randomized Controlled Trials as Topic/*methods, Schentag Jerome J, Streptococcus pneumoniae/*isolation & purification, Time Factors, Treatment Outcome

SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia.

BACKGROUND: Solithromycin, a novel macrolide antibiotic with both intravenous and oral formulations dosed once daily, has completed 2 global phase 3 trials for treatment of community-acquired bacterial pneumonia. METHODS: A total of 863 adults with…

Tags: *clinical trial, *Community-acquired, *Pneumonia, *solithromycin, *Streptococcus pneumoniae, 2016, 80 and over, Administration, Adult, Aged, Anti-Bacterial Agents/*administration & dosage/adverse effects, Bacterial, Bacterial/diagnosis/*drug therapy/*microbiology, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Community-Acquired Infections/diagnosis/*drug therapy/*microbiology, Comorbidity, Das Anita F, Department of Internal Medicine, Drug Resistance, Female, Fernandes Prabhavathi, File Thomas M Jr, Fluoroquinolones/*administration & dosage/adverse effects, Gonong Joven Roque V, Humans, Intravenous, Jamieson Brian D, Keedy Kara, Macrolides/*administration & dosage/adverse effects, Male, Microbial Sensitivity Tests, Middle Aged, Moxifloxacin, NEOMED College of Medicine, Oldach David, Oral, Pneumonia, Rewerska Barbara, Sheets Amanda, Taylor David, Treatment Outcome, Triazoles/*administration & dosage/adverse effects, Vucinic-Mihailovic Violeta

A disease model descriptive of progression between chronic obstructive pulmonary disease exacerbations and community-acquired pneumonia: roles for underlying lung disease and the pharmacokinetics/pharmacodynamics of the antibiotic.

Patients with chronic obstructive pulmonary disease (COPD) may progress to community-acquired pneumonia (CAP), but there has been no formal study of the factors responsible. We studied the influence of severity of underlying lung disease, pathogen…

Tags: *Anti-Bacterial Agents/pharmacokinetics/therapeutic use, *Community-Acquired Infections/drug therapy/microbiology/physiopathology/prevention & control, *Models, *Pneumonia, 2009, Adelman Martin H, Aged, Area Under Curve, Bacterial/drug therapy/microbiology/physiopathology/prevention & control, Biological, Bronchitis, Chronic Obstructive/drug therapy/microbiology/*physiopathology, Chronic/drug therapy/microbiology/physiopathology, Department of Internal Medicine, Disease Progression, Female, File Thomas M Jr, Humans, International journal of antimicrobial agents, Klugman Keith P, Lavin Bruce, Lung Diseases/complications/drug therapy/microbiology, Lung/microbiology, Male, Microbial Sensitivity Tests, Middle Aged, Monte Scott V, NEOMED College of Medicine, Paladino Joseph A, Pneumococcal/drug therapy/microbiology/physiopathology/prevention & control, Pneumonia, Pulmonary Disease, Schentag Jerome J, Severity of Illness Index, Singer Mendel E, Streptococcus pneumoniae/*drug effects, Yu Victor L

Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumonia.

OBJECTIVE: To evaluate the time to symptom resolution and i.v.-to-p.o. transition in community-acquired pneumonia (CAP) patients treated with 750 mg or 500 mg levofloxacin. RESEARCH DESIGN: A retrospective, subset analysis of a multicenter,…

Burden of community-acquired pneumonia in North American adults.

To determine the burden of community-acquired pneumonia (CAP) affecting adults in North America, a comprehensive literature review was conducted to examine the incidence, morbidity and mortality, etiology, antibiotic resistance, and economic impact…

Tags: 2010, Adult, Bacterial – Economics, Bacterial – Epidemiology, Bacterial – Microbiology, Bacterial – Mortality, Bacterial – Prevention and Control, Bacterial/economics/*epidemiology/microbiology/prevention & control, Community-Acquired Infections – Economics, Community-Acquired Infections – Epidemiology, Community-Acquired Infections – Microbiology, Community-Acquired Infections – Prevention and Control, Community-Acquired Infections/economics/epidemiology/microbiology/prevention & control, Cost of Illness, Department of Internal Medicine, Economic Aspects of Illness, File Thomas M Jr, Health Care Costs, Health Status Indicators, Hospitalization – Economics, Hospitalization – Statistics and Numerical Data, Hospitalization/economics/statistics & numerical data, Human, Humans, Incidence, Length of Stay – Statistics and Numerical Data, Length of Stay/statistics & numerical data, Marrie Thomas J, NEOMED College of Medicine, North America, North America/epidemiology, Pneumococcal Vaccine, Pneumococcal Vaccines, Pneumococcal/economics/epidemiology/mortality/prevention & control, Pneumonia, Postgraduate medicine, Risk Factors, Streptococcus, Streptococcus pneumoniae

Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study.

OBJECTIVES: Short-course therapy has been advocated for the treatment of community-acquired pneumonia (CAP). We compared the efficacy and safety of 5 and 7 day courses of gemifloxacin for outpatient treatment of mild-moderate CAP. PATIENTS AND…

Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia.

BACKGROUND: Ceftaroline, the active form of ceftaroline fosamil, is a broad-spectrum cephalosporin with bactericidal activity against pathogens causing community-acquired pneumonia (CAP), including Streptococcus pneumoniae. Ceftaroline was evaluated…

FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.

OBJECTIVES: Ceftaroline, the active form of the prodrug ceftaroline fosamil, is a novel cephalosporin with bactericidal activity against important pathogens associated with community-acquired pneumonia (CAP), including Streptococcus pneumoniae and…

Tags: 2011, 80 and over, Aged, Bacteria, Bacteria/isolation & purification, Bacterial – Drug Therapy, Bacterial/*drug therapy, Ceftriaxone – Administration and Dosage, Ceftriaxone – Adverse Effects, Ceftriaxone/administration & dosage/adverse effects, Cephalosporins – Administration and Dosage, Cephalosporins – Adverse Effects, Cephalosporins/*administration & dosage/*adverse effects, Community-Acquired Infections – Drug Therapy, Community-Acquired Infections/*drug therapy, Critchley Ian A, Department of Internal Medicine, Double-Blind Method, Double-Blind Studies, Eckburg Paul B, Female, File Thomas M Jr, Friedland H David, Human, Humans, Infusions, Intravenous, Lee Jon, Llorens Lily, Low Donald E, Male, Middle Age, Middle Aged, NEOMED College of Medicine, Pneumonia, RANDOMIZED controlled trials, Talbot George H, The Journal of antimicrobial chemotherapy, Thye Dirk A, Treatment Outcome, Treatment Outcomes

Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxycillin/clavulanate.

The efficacy of a new pharmacokinetically enhanced formulation of amoxycillin/clavulanate (AMX/CA) 2000/125 mg, twice daily, designed to provide adequate levels of amoxycillin over the 12-h dosing interval to eradicate penicillin-resistant…

Tags: *Treatment Outcome, 2002, 80 and over, Adolescent, Adult, Aged, Amoxicillin-Potassium Clavulanate Combination/administration & dosage/*pharmacokinetics/pharmacology/*therapeutic use, Amoxicillin/adverse effects/therapeutic use, Bacterial, Bacterial/drug therapy/immunology, Bronchitis/drug therapy/microbiology, Combination/adverse effects/*therapeutic use, Department of Internal Medicine, Double-Blind Method, Drug Administration Schedule, Drug Resistance, Drug Therapy, Female, File Thomas M Jr, Follow-Up Studies, Humans, International journal of antimicrobial agents, Jacobs Michael R, Male, Microbial Sensitivity Tests, Middle Aged, Multicenter Studies as Topic, NEOMED College of Medicine, Pneumonia, Poole Michael D, Respiratory Tract Infections/*drug therapy/metabolism/microbiology, Streptococcal Infections/*drug therapy/metabolism/microbiology, Streptococcus pneumoniae/*drug effects, Wynne Brian

Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia.

Empiric antimicrobial prescribing for community-acquired pneumonia remains a challenge, despite the availability of treatment guidelines. A number of key differences exist between North American and European guidelines, mainly in the outpatient…

Macrolide therapy for community-acquired pneumonia due to atypical pathogens: outcome assessment at an early time point.

BACKGROUND: Therapy directed against atypical pathogens in patients with community-acquired pneumonia (CAP) is often recommended. This post-hoc analysis evaluated the effect of addition of a macrolide to ceftaroline fosamil or ceftriaxone treatment…

Tags: 2017, 80 and over, Adult, Aged, Anti-Bacterial Agents/adverse effects/*therapeutic use, Atypical pathogen, Bacterial/*drug therapy, Ceftaroline fosamil, Ceftriaxone/adverse effects/*therapeutic use, Cephalosporins/adverse effects/*therapeutic use, Chlamydial Pneumonia, Chlamydophila pneumoniae, Clinical Trials, Combination/adverse effects/methods, Community-Acquired Infections/*drug therapy, Community-acquired pneumonia, Department of Internal Medicine, Double-Blind Method, Drug Therapy, Eckburg Paul B, Female, File Thomas M Jr, Friedland H David, Humans, International journal of antimicrobial agents, Legionella pneumophila, Llorens Lily, Macrolide, Macrolides/adverse effects/*therapeutic use, Male, Middle Aged, Mycoplasma, Mycoplasma pneumoniae, NEOMED College of Medicine, Phase III as Topic, Pneumonia, Randomized Controlled Trials as Topic, Talbot George H, Time Factors, Treatment Outcome

Browse Items (66 total)